BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 23054316)

  • 1. The lipid story in chronic kidney disease: a long story with a happy end?
    Kujawa-Szewieczek A; Więcek A; Piecha G
    Int Urol Nephrol; 2013 Oct; 45(5):1273-87. PubMed ID: 23054316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge.
    Rysz J; Gluba-Brzózka A; Banach M; Więcek A
    Int Urol Nephrol; 2015 May; 47(5):805-13. PubMed ID: 25758011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins for treatment of dyslipidemia in chronic kidney disease.
    Shurraw S; Tonelli M
    Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is lipid management effective for all stages of CKD?
    Ku E; Campese V
    Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
    Karie S; Launay-Vacher V; Deray G; Isnard-Bagnis C
    Presse Med; 2006 Feb; 35(2 Pt 1):219-29. PubMed ID: 16493350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Statins: what is their place in the treatment of chronic kidney insufficiency?].
    Ponte B; Bourquin V; Stoermann-Chopard C
    Rev Med Suisse; 2009 Feb; 5(192):463-4, 466-8. PubMed ID: 19317313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyslipidemia in Patients with Kidney Disease.
    Thobani A; Jacobson TA
    Cardiol Clin; 2021 Aug; 39(3):353-363. PubMed ID: 34247749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
    Vaziri ND; Norris KC
    Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
    Scarpioni R; Ricardi M; Melfa L; Cristinelli L
    Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era.
    Heymann EP; Kassimatis TI; Goldsmith DJ
    J Nephrol; 2012; 25(4):460-72. PubMed ID: 22641572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants.
    Barylski M; Nikfar S; Mikhailidis DP; Toth PP; Salari P; Ray KK; Pencina MJ; Rizzo M; Rysz J; Abdollahi M; Nicholls SJ; Banach M;
    Pharmacol Res; 2013 Jun; 72():35-44. PubMed ID: 23542730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipidemia in patients with chronic kidney disease.
    Hager MR; Narla AD; Tannock LR
    Rev Endocr Metab Disord; 2017 Mar; 18(1):29-40. PubMed ID: 28000009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease.
    Peev V; Nayer A; Contreras G
    Curr Opin Lipidol; 2014 Feb; 25(1):54-60. PubMed ID: 24345987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins and renal disease: friend or foe?
    Deshmukh A; Mehta JL
    Curr Atheroscler Rep; 2011 Feb; 13(1):57-63. PubMed ID: 21053107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based statin prescription for cardiovascular protection in renal impairment.
    Fabbian F; De Giorgi A; Pala M; Tiseo R; Manfredini R; Portaluppi F
    Clin Exp Nephrol; 2011 Aug; 15(4):456-63. PubMed ID: 21556807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.
    Kanbay M; Turgut F; Covic A; Goldsmith D
    J Nephrol; 2009; 22(5):598-609. PubMed ID: 19809992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid management in patients with chronic kidney disease.
    Ferro CJ; Mark PB; Kanbay M; Sarafidis P; Heine GH; Rossignol P; Massy ZA; Mallamaci F; Valdivielso JM; Malyszko J; Verhaar MC; Ekart R; Vanholder R; London G; Ortiz A; Zoccali C
    Nat Rev Nephrol; 2018 Dec; 14(12):727-749. PubMed ID: 30361677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins in the management of dyslipidemia associated with chronic kidney disease.
    Epstein M; Vaziri ND
    Nat Rev Nephrol; 2012 Feb; 8(4):214-23. PubMed ID: 22349484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins in chronic kidney disease and kidney transplantation.
    Kassimatis TI; Goldsmith DJ
    Pharmacol Res; 2014 Oct; 88():62-73. PubMed ID: 24995940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.